Oppenheimer Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its price objective raised by analysts at Oppenheimer from $128.00 to $165.00 in a report issued on Wednesday,MarketScreener reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Oppenheimer’s price target indicates a potential upside of 8.69% from the company’s current price.

GILD has been the topic of several other research reports. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday. BMO Capital Markets boosted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Royal Bank Of Canada upped their target price on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a research note on Wednesday. Cantor Fitzgerald raised their target price on Gilead Sciences from $135.00 to $155.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $152.42.

Gilead Sciences Trading Down 2.6%

Gilead Sciences stock opened at $151.81 on Wednesday. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The firm has a market capitalization of $188.35 billion, a PE ratio of 22.42, a PEG ratio of 0.81 and a beta of 0.36. The business’s 50-day simple moving average is $129.59 and its 200-day simple moving average is $121.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the prior year, the business earned $1.90 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares in the company, valued at $92,086,800. The trade was a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at $1,101,620. This trade represents a 35.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 319,391 shares of company stock worth $44,141,101. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GILD. Paulson Wealth Management Inc. boosted its stake in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares during the last quarter. Essex Financial Services Inc. lifted its stake in shares of Gilead Sciences by 0.9% in the 4th quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock valued at $948,000 after purchasing an additional 71 shares during the period. Alpha Cubed Investments LLC boosted its position in shares of Gilead Sciences by 1.1% in the 4th quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after purchasing an additional 75 shares during the last quarter. Personal CFO Solutions LLC boosted its position in shares of Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 76 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 1.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after purchasing an additional 76 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat consensus — revenue and EPS topped estimates, driven by HIV and liver‑disease portfolio strength and early traction for new products; this underpins analyst bullishness and longer‑term revenue visibility. GILD’s Q4 Earnings Beat
• Positive Sentiment: Big wave of analyst price‑target increases and buy/outperform notes (examples: Morgan Stanley $171, Scotiabank $177, Needham/Wolfe $170, Wells Fargo & JPMorgan mid‑$160s) — brokers cite HIV momentum, margin expansion and product pipeline (Yeztugo, Yescarta) as reasons to raise targets. Analyst Coverage Summary
• Positive Sentiment: Dividend increase announced — quarterly dividend up to $0.82 (3.8% raise), supporting income investor appeal and signaling management confidence in cash flow.
• Neutral Sentiment: Earnings call / transcripts published (multiple outlets) — useful for detail on guidance assumptions, product rollouts and cost/margin outlook but neutral until investors parse management commentary. Earnings Call Transcript
• Neutral Sentiment: Yescarta label expansion and new product commentary appear in coverage — potential medium‑term upside if uptake meets expectations; currently a pipeline/progression read‑through. Yescarta & Dividend Coverage
• Neutral Sentiment: Short‑interest notes in data feeds show anomalous 0 shares / NaN changes — not meaningful evidence of a short squeeze or new bearish positioning based on available figures.
• Negative Sentiment: FY‑2026 guidance came in below some Street expectations — management’s outlook tempered the post‑earnings rally and is the principal reason for the intraday/extended‑session pullback despite the beat. Guidance / Shares Dip
• Negative Sentiment: At least one broker adjustment (Royal Bank of Canada) shows a lower relative price target in published feeds despite a PT raise vs. prior internal note — highlights disagreement among analysts on near‑term valuation and reinforces guidance‑driven uncertainty. RBC / Ticker Report

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.